Table 1. Patient-, tumor- and treatment-related characteristics.

Case #	Age (yr)	BMI (kg/m2)	Previous pregnancy	Diagnostic method	Tumor diameter (cm)	Diagnostic laparoscopy	Fertility-sparing treatment modalities	Progestin therapy (mo)
1	39	24.3	-	Office HSC with EB	>2	Yes	HR + LNG-IUD	3
2	32	36.5	-	Office HSC with EB	>2	No	HR + LNG-IUD	9
3	31	21.4	-	D&C	≤2	Yes	HR + MA (160 mg/d)	11
4	33	29.3	-	HSC followed by D&C	≤2	Yes	HR + MA (160 mg/d)	3
5	31	24	-	HSC followed by D&C	≤2	Yes	HR + MA (160 mg/d)	22
6	28	42	1 NFTD; 1 SFTM	HSC followed by D&C	≤2	No	HR + LNG-IUD	24
7	32	30	-	HSC followed by D&C	≤2	No	HR + LNG-IUD	6
8	37	24	-	Office HSC with EB	≤2	No	MA (160 mg/d)	13
9	34	23.5	-	HSC followed by D&C	≤2	No	HR + LNG-IUD	12
10	37	24	-	Office HSC with EB	n/a	Yes	LNG-IUD	14
11	43	21	-	Office HSC with EB	n/a	Yes	LNG-IUD	32
12	28	31	-	Office HSC with EB	n/a	Yes	LNG-IUD	36
13	31	29	-	Office HSC with EB	n/a	Yes	LNG-IUD	46
14	36	26	2 NFTDs	Office HSC with EB	≤2	No	HR + MA (160 mg/d)	12
15	37	24.1	-	Office HSC with EB	n/a	No	HR + LNG-IUD	6
16	31	19.8	-	Office HSC with EB	n/a	No	HR + LNG-IUD	6
17	28	38.3	-	Office HSC with EB	n/a	No	HR + LNG-IUD	26
18	40	21.3	1 NFTD	Office HSC with EB	>2	No	HR + LNG-IUD	10
19	44	28.9	1 NFTD; 2 SFTMs; 1 EA	Office HSC with EB	>2	No	HR + LNG-IUD	6
20	42	34.1	-	Office HSC with EB	≤2	No	HR + NET (10 mg/d)	9
21	32	31.6	-	Office HSC with EB	≤2	No	LNG-IUD + MA (160 mg/d)	6
22	34	31.2	1 SFTM	Office HSC with EB	n/a	No	HR + LNG-IUD	8
23	37	34.9	-	Office HSC with EB	n/a	No	HR + LNG-IUD	77

BMI, body mass index; D&C, dilation and curettage; EA, elective abortion; EB, endometrial biopsy; HR, hysteroscopic resection; HSC, hysteroscopy; LNG-IUD, levonorgestrel intrauterine device; MA, megestrol acetate; n/a, not available; NET, norethisterone acetate; NFTD, normal full-term delivery; SFTM, spontaneous first-trimester miscarriage.